For a long time, the chances of surviving pancreatic cancer were very low. Among patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, approximately 97% died within five years of diagnosis.
Pancreatic cancer is so deadly, in part because there are no effective screening tests and because it causes few noticeable symptoms in its early stages. By the time a patient experiences signs such as jaundice (yellowing of the skin) or abdominal pain, the cancer has often already spread to other organs.
As a gastrointestinal oncologist and researcher specializing in early-stage clinical trials, I have long recognized that there is a critical need for more effective treatments for patients with pancreatic cancer. For decades, it was thought impossible to successfully target the central mechanisms that cause the majority of pancreatic cancers.
However, this situation is rapidly changing with the advent of new drugs that can block key proteins that cause pancreatic cancer, nearly doubling survival rates for patients in advanced stages of the disease.
“Untreatable” tumors
Standard treatment for advanced pancreatic cancer has historically relied on chemotherapy, powerful drugs designed to kill rapidly dividing cells. Chemotherapy can slow disease progression, but its effectiveness is often limited by the ability of pancreatic cancer cells to develop resistance to these drugs.
The key to pancreatic cancer success lies in its genetics. More than 90% of pancreatic tumors are caused by mutations in a gene called KRAS. This gene codes for a protein that acts as a switch to turn cell growth on and off. When the KRAS gene mutates, it permanently locks a switch in the “on” position, telling cancer cells to multiply indefinitely.
For decades, scientists thought KRAS was “untreatable.” The surface of the protein is very smooth and lacks the molecular pockets that standard drugs need to bind and switch off.
Because existing drugs cannot target this protein, treatments for pancreatic cancer have relied primarily on toxic drugs that act more like blunt instruments than precision tools. Chemotherapy attempts to control the disease through extensive cell destruction, but causes significant collateral damage to healthy tissue and causes side effects.
What is Darathon Lasib?
A new drug called dalaxone lasib represents a significant advance in the treatment of metastatic pancreatic cancer.
Daraxone lasib is taken orally daily. Instead of binding directly to KRAS, it binds to a molecule called cyclophilin A in the cell, which helps fold the protein into its final 3D structure. This protein complex binds to the active KRAS protein and blocks its ability to signal cancer cells to proliferate.
Revolution Medicines, the company developing the drug, announced on May 31, 2026, the results of a Phase 3 clinical trial involving 500 patients with previously treated metastatic pancreatic cancer. Compared to standard chemotherapy, dalaxone lasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. Overall, daraxone lasib reduced the risk of death in patients with metastatic pancreatic cancer by 60%.
The most common side effect was a noticeable skin rash, which affected more than 86% of patients in the study. Patients also frequently suffered from canker sores, including painful swelling and sores inside the mouth, as well as diarrhea, nausea, and vomiting. However, patients taking daraxone lasib were far less likely to discontinue treatment due to severe side effects compared with chemotherapy, and experienced reduced pain and improved quality of life.
Darathon Lasiv’s next step
Researchers have successfully targeted a specific genetic mutation that causes the majority of pancreatic cancers, demonstrating that this “untreatable” disease can be treated with targeted therapy.
The immediate next step is regulatory review of the drug’s readiness in clinical practice. Now that the data has been officially published, Revolution Medicines plans to use these findings to seek formal approval from the Food and Drug Administration and other global regulatory bodies.
Because advanced pancreatic cancer is notoriously difficult to treat, breakthrough treatments of this type that demonstrate significant survival benefits are often granted accelerated or priority review. When daroxone lasib will be available to patients will depend on the review timeline. If the drug receives approval, it could be available in clinics within months.
For the broader context of drug development, this milestone represents a likely shift in pancreatic cancer treatment. We hope to see more clinical trials exploring combination therapy combining KRAS inhibitors with other drugs to prevent tumors from developing treatment resistance.
If dalaxone lasib is successful, it could pave the way for more precise, personalized, and effective treatments for pancreatic cancer in the coming years.
